Zacks Investment Research
20 Oct 2026, 22:51 UTC · 1h ago
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
Impact · against what's priced in
The article provides consensus estimates for ADMA that are already factored into the current valuation. No new material catalysts were identified, as the projected earnings and revenue growth are existing market expectations.
- ADMA+0.00
No priced-in read yet
- In context
The projected quarterly EPS of $0.19 and full-year revenue of $536.82 million are consensus estimates and do not represent a surprise to the market.
Read from the article alone
Top 2 movers · tap to explore
